Teva has announced that the US FDA has approved its tobramycin inhalation solution, a generic equivalent to Novartis’s TOBI inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients. According to Teva, the company will launch the product in November 2013 in accordance with an agreement with Novartis.
Read the Teva press release.
